Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

about

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

Item

http://www.wikidata.org/entity/Q54449204

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@en

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@nl

type

Item

label

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@en

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@nl

prefLabel

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@en

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@nl

P1476

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.

@en

P2093

Jeffrey S Hyams

http://www.w3.org/2001/XMLSchema#string

Marla C Dubinsky

http://www.w3.org/2001/XMLSchema#string

Subra Kugathasan

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.

A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.

Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

P304

1774-1776

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1097/MIB.0000000000001206

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28837525

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases